SEBERANG PERAI, Malaysia, May 17, 2025 /PRNewswire/ -- Trensor Electronics Sdn Bhd, the Malaysian subsidiary of Trensor Co Ltd—a leading manufacturer of automotive pressure sensors—held a groundbreaking ceremony to mark the commencement of construction on its new manufacturing plant at the Penang Technology Park @Bertam in Penang, Malaysia.
The new plant—a four-storey facility with an approximate floor area of 10,000 square meters and an estimated investment of RM100 million—is expected to begin mass production of automotive pressure sensors before Q2 2026. At full capacity, it will employ over 200 workers and generate more than RM200 million in annual sales. Trensor has also reserved space on its current land lots to accommodate future expansions.
The ceremony was attended by YAB Chow Kon Yeow, the Chief Minister of Penang, YB H'ng Mooi Lye, the Penang State Executive Councillor (EXCO) for Local Government and Town&Country Planning, as well as representatives from various local organizations, including the Malaysian Investment Development Authority (MIDA), Northern Corridor Implementation Authority (NCIA) and InvestPenang.
In his speech, YAB Chow Kon Yeow welcomed Trensor's entry into Penang's vibrant industrial ecosystem and emphasized its role in strengthening the state's electrical and electronics value chain, particularly in automotive electronics.
Zhou Wenbo, General Manager of Trensor Electronics Sdn Bhd, stated: "The decision by Trensor Co Ltd to establish its first-ever overseas factory in Penang, Malaysia, was driven by the state's world-class infrastructure, business-friendly governance, high quality of life, cultural affinity, and abundant pool of high-tech talent attracted to the 'Silicon Valley of the East'."
"MIDA, InvestPenang, the Seberang Perai City Council, and all local authorities have provided strong support in helping Trensor turn its globalization strategy into a concrete reality today," Zhou added.
Trensor Co Ltd specializes in the development and manufacture of automotive pressure sensors, ranking highly in annual output, automation, and vertical integration. Its world-class products are included in the procurement systems of major global automakers such as Ford and Geely, as well as Tier 1 suppliers like Cummins and Hanon Systems. Approximately 60% of the company's revenue is derived from exports, primarily to North America and Europe. Its pressure sensors are also used in the air conditioning systems of Perodua vehicles.
The Penang facility will support Trensor's strategic expansion into Southeast Asia's growing automotive markets and beyond.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Trensor Breaks Ground on First Factory in Malaysia
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
